Cart
sales@molnova.com
dBRD9
CAS No. 2170679-45-3
dBRD9 ( dBRD 9 )
Catalog No. M13465 CAS No. 2170679-45-3
dBRD9 is a PROTAC that bridge the BRD9 bromodomain and the cereblon E3 ubiquitin ligase complex.
Purity : >98% (HPLC)
COA
Datasheet
HNMR
HPLC
MSDS
Handing Instructions
| Size | Price / USD | Stock | Quantity |
| 5MG | 295 | Get Quote |
|
| 10MG | 475 | Get Quote |
|
| 25MG | 828 | Get Quote |
|
| 50MG | 1251 | Get Quote |
|
| 100MG | 1737 | Get Quote |
|
| 200MG | Get Quote | Get Quote |
|
| 500MG | Get Quote | Get Quote |
|
| 1G | Get Quote | Get Quote |
|
Biological Information
-
Product NamedBRD9
-
NoteResearch use only, not for human use.
-
Brief DescriptiondBRD9 is a PROTAC that bridge the BRD9 bromodomain and the cereblon E3 ubiquitin ligase complex.
-
DescriptiondBRD9 is a PROTAC that bridge the BRD9 bromodomain and the cereblon E3 ubiquitin ligase complex; exhibits markedly enhanced potency compared to parental ligands (10-100 fold).
-
SynonymsdBRD 9
-
PathwayPROTACs
-
TargetPROTAC
-
RecptorPROTAC
-
Research Area——
-
Indication——
Chemical Information
-
CAS Number2170679-45-3
-
Formula Weight783.84
-
Molecular FormulaC40H45N7O10
-
Purity>98% (HPLC)
-
Solubility——
-
SMILESO=C(NCCOCCOCCNC1=CC=CC(C(N2C(CC3)C(NC3=O)=O)=O)=C1C2=O)CN(CC4=C(OC)C=C(C(C5=CC=NC=C65)=CN(C)C6=O)C=C4OC)C
-
Chemical Name2-((2,6-dimethoxy-4-(2-methyl-1-oxo-1,2-dihydro-2,7-naphthyridin-4-yl)benzyl)(methyl)amino)-N-(2-(2-(2-((2-(2,6-dioxopiperidin-3-yl)-1,3-dioxoisoindolin-4-yl)amino)ethoxy)ethoxy)ethyl)acetamide
Shipping & Storage Information
-
Storage(-20℃)
-
ShippingWith Ice Pack
-
Stability≥ 2 years
Reference
1. Remillard D, et al. Angew Chem Int Ed Engl. 2017 May 15;56(21):5738-5743.
molnova catalog
related products
-
Bromo-PEG3-C2-acid
Bromo-PEG3-C2-acid is a PEG-based PROTAC linker that can be used in the synthesis of PROTACs.
-
6-Maleimidocapronic ...
6-Maleimidocapronic acid is an alkyl chain-based PROTAC linker that can be used in the synthesis of PROTACs.
-
Amino-PEG11-amine
Amino-PEG11-amine, a PEG-based (12 units) PROTAC linker used to combine two mono diethylstilbestrol (DES)-based ligands, provides an alternative strategy for preparing more selective and active ER antagonists for endocrine therapy of breast cancer.
